Nimble Therapeutics

Madison, United States Founded: 2019 • Age: 7 yrs Acquired By AbbVie
Combinatorial chemistry services for peptide-based drug discovery are provided.
Request Access

About Nimble Therapeutics

Nimble Therapeutics is a company based in Madison (United States) founded in 2019 was acquired by AbbVie in December 2024.. Nimble Therapeutics has raised $10 million across 1 funding round from investors including AbbVie and Telegraph Hill Partners. The company has 24 employees as of December 31, 2021. Nimble Therapeutics operates in a competitive market with competitors including Aqemia, NTxBio, Applied BioMath, Enveda and IMIDomics, among others.

  • Headquarter Madison, United States
  • Employees 24 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Nimble Therapeutics, Inc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $10 M (USD)

    in 1 rounds

  • Latest Funding Round
    $10 M (USD), Series A

    Apr 30, 2019

  • Investors
    AbbVie

    & 1 more

  • Employee Count
    24

    as on Dec 31, 2021

  • Acquired by
    AbbVie

    (Dec 13, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Nimble Therapeutics
Headcount 10-50
Employee Profiles 12
Board Members and Advisors 3
Employee Profiles
People
Jigar Patel
Founder & CEO
People
Andrew Wagner
Director, Software & Engineering
People
Brad Garcia
VP, Corporate Development
People
Eric Dauenhauer
Principal Engineer

Unlock access to complete

Funding Insights of Nimble Therapeutics

Nimble Therapeutics has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $10.0M
  • First Round

    (30 Apr 2019)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2019 Amount Series A - Nimble Therapeutics Valuation Telegraph Hill Partners
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Nimble Therapeutics

Nimble Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie and Telegraph Hill Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on life science, medical device and healthcare companies
Founded Year Domain Location
Biopharmaceutical research and drug development are conducted globally by AbbVie.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Nimble Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Nimble Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Nimble Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Nimble Therapeutics

Nimble Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aqemia, NTxBio, Applied BioMath, Enveda and IMIDomics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutic molecules are discovered through AI and quantum physics integration.
domain founded_year HQ Location
Provider of bio informatics platform to develops biologics and therapeutics
domain founded_year HQ Location
Systems biology and pharmacology modeling services to aid drug discovery and development
domain founded_year HQ Location
Provider of AI-based platform to decipher the chemistry of nature and develop new medicines
domain founded_year HQ Location
Precision medicines for immune-mediated inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Nimble Therapeutics

Frequently Asked Questions about Nimble Therapeutics

When was Nimble Therapeutics founded?

Nimble Therapeutics was founded in 2019.

Where is Nimble Therapeutics located?

Nimble Therapeutics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.

Is Nimble Therapeutics a funded company?

Nimble Therapeutics is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series A of $10M, raised on Apr 30, 2019.

How many employees does Nimble Therapeutics have?

As of Dec 31, 2021, the latest employee count at Nimble Therapeutics is 24.

What does Nimble Therapeutics do?

Nimble Therapeutics was founded in 2019 in Madison, United States, within the biotechnology sector. Drug discovery services centered on combinatorial chemistry are offered, with a focus on peptide technologies. A chemical synthesis platform has been developed to facilitate the creation and evaluation of various peptides, including scaffolded natural and modified macrocyclic peptidomimetics. Operations emphasize efficient screening processes for potential therapeutic compounds in the pharmaceutical industry.

Who are the top competitors of Nimble Therapeutics?

Nimble Therapeutics's top competitors include Aqemia, NTxBio and Enveda.

Who are Nimble Therapeutics's investors?

Nimble Therapeutics has 2 investors. Key investors include AbbVie, and Telegraph Hill Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available